The report highlights the company's commitment to ESG practices and social responsibility performances. It describes the company's efforts in business operation and development, environment conservation, employees and community, as well as chain optimization. The report also highlights the company's achievements in R&D and commercialization of innovative vaccines, particularly its progress in developing a COVID-19 vaccine for inhalation, a recombinant poliomyelitis vaccine, and a tetravalent meningococcal conjugate vaccine. The report concludes with a focus on the company's commitment to community care, particularly its efforts to provide access to healthcare, community care, and public welfare activities.
Issuing Company Cansino Biologics Inc.
Report Type Sustainability Report
Report Language EN
Report Filesize 12.25 MB
No. of Pages 117 pages
Reporting periodJanuary 1, 2023-December 31, 2023
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards GRI; SASB; UNSDGs
Materiality Assessmenttrue